SunTrust Banks Trims Health Catalyst (NASDAQ:HCAT) Target Price to $35.00
Health Catalyst (NASDAQ:HCAT) had its price objective decreased by SunTrust Banks from $46.00 to $35.00 in a research report issued on Thursday, BenzingaRatingsTable reports. The brokerage currently has a “buy” rating on the stock. SunTrust Banks’ price objective indicates a potential upside of 38.39% from the stock’s previous close.
HCAT has been the subject of several other research reports. Zacks Investment Research downgraded shares of Health Catalyst from a “buy” rating to a “hold” rating in a research report on Saturday, January 4th. ValuEngine upgraded Health Catalyst from a “hold” rating to a “buy” rating in a report on Tuesday, February 18th. Finally, Raymond James began coverage on Health Catalyst in a report on Thursday, December 19th. They issued a “strong-buy” rating and a $46.00 target price on the stock. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $46.33.
Shares of HCAT stock traded down $0.52 on Thursday, reaching $25.29. The company had a trading volume of 51,931 shares, compared to its average volume of 787,415. The stock has a market capitalization of $1.02 billion and a PE ratio of -17.81. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.25. Health Catalyst has a one year low of $17.48 and a one year high of $49.85. The business’s 50-day moving average is $28.53 and its 200 day moving average is $32.61.
In other news, CTO Dale Sanders sold 27,500 shares of Health Catalyst stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $28.46, for a total transaction of $782,650.00. Following the sale, the chief technology officer now directly owns 88,728 shares in the company, valued at approximately $2,525,198.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Paul Horstmeier sold 10,750 shares of Health Catalyst stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $28.53, for a total value of $306,697.50. Following the sale, the chief operating officer now owns 85,750 shares in the company, valued at $2,446,447.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,194 shares of company stock worth $1,601,290.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Altshuler Shaham Ltd bought a new stake in shares of Health Catalyst during the 4th quarter worth $27,000. Citigroup Inc. increased its holdings in Health Catalyst by 438.8% in the 4th quarter. Citigroup Inc. now owns 2,015 shares of the company’s stock worth $70,000 after acquiring an additional 1,641 shares during the last quarter. Metropolitan Life Insurance Co NY purchased a new stake in Health Catalyst in the 3rd quarter worth about $161,000. California Public Employees Retirement System purchased a new stake in Health Catalyst in the 3rd quarter worth about $202,000. Finally, New York State Common Retirement Fund increased its holdings in Health Catalyst by 9.4% in the 4th quarter. New York State Common Retirement Fund now owns 7,000 shares of the company’s stock worth $243,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 62.88% of the company’s stock.
About Health Catalyst
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its products include analytics platform, accountable care and financial, benchmarking and comparative analytics, care management and population health, clinical analytics, operations and performance management, patient safety, and services.
Recommended Story: Why does the United States have a lingering trade deficit?
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.